

DAFTAR PUSTAKA

- Bakris, G., Pitt, B., Weir, M., Freeman, M., Mayo, M., Garza, D., dkk., 2015, Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: the AMETHYST-DN Randomized Clinical Trial, *JAMA*, **314**: 151-161.
- Bandak, G., Sang, Y., Gasparini, A., Chang, A.R., Ballew, S.H., Evans, M., dkk., 2017, Hyperkalemia After Initiating Renin–Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project, *Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease*, **6**: e005428.
- Chang, A.R., Sang, Y., Leddy, J., Yahya, T., Kirchner, H.L., Inker, L.A., dkk., 2016, Antihypertensive Medications and the Prevalence of Hyperkalemia in a Large Health System, *Hypertension*, **67**: 1181–1188.
- Chernin, G., Gal-Oz, A., Ben-Assa, E., Schwartz, I.F., Weinstein, T., Schwartz, D., dkk., 2012, Secondary Prevention of Hyperkalemia With Sodium Polystyrene Sulfonate in Cardiac and Kidney Patients on Renin-Angiotensin-Aldosterone System Inhibition Therapy, *Clinical Cardiology*, **35**: 32–36.
- Cheung, A.K., Chang, T.I., Cushman, W.C., Furth, S.L., Hou, F.F., Ix, J.H., dkk., 2021, KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease, *Kidney International*, **99**: S1–S87.
- Desai, N.R., Rowan, C.G., Alvarez, P.J., Fogli, J., dan Toto, R.D., 2020, Hyperkalemia treatment modalities: A descriptive observational study focused on medication and healthcare resource utilization, *PLoS One*, **15**: .
- Espinel, E., Joven, J., Gil, I., Suñé, P., Renedo, B., Fort, J., dkk., 2013, Risk of hyperkalemia in patients with moderate chronic kidney disease initiating angiotensin converting enzyme inhibitors or angiotensin receptor blockers: a randomized study, *BMC Research Notes*, **6**: 306.
- Fröhlich, H., Nelges, C., Täger, T., Schwenger, V., Cebola, R., Schnorbach, J., dkk., 2016, Long-term changes of renal function in relation to ace inhibitor/angiotensin receptor blocker dosing in patients with heart failure and chronic kidney disease, *The American Heart Journal*, **178**: 28–36.
- Georgianos, P.I., Liampas, I., Kyriakou, A., Vaios, V., Raptis, V., Savvidis, N., dkk., 2017, Evaluation of the tolerability and efficacy of sodium polystyrene sulfonate for long-term management of hyperkalemia in patients with chronic kidney disease, *International Urology and Nephrology*, **49**: 2217–2221.
- Herman, L.L., Padala, S.A., Ahmed, I., dan Bashir, K., 2021, Angiotensin Converting Enzyme Inhibitors (ACEI), dalam: *StatPearls*, StatPearls Publishing, Treasure Island (FL).
- Hill, R.D. dan Vaidya, P.N., 2021, Angiotensin II Receptor Blockers (ARB), dalam: *StatPearls*, StatPearls Publishing, Treasure Island (FL).

- Hudson, J.Q. dan Wazny, L.D., 2017, Chronic Kidney Disease, dalam: *Pharmacotherapy: A Pathophysiologic Approach*, McGraw Hill, New York.
- Hunter, R.W. dan Bailey, M.A., 2019, Hyperkalemia: pathophysiology, risk factors and consequences, *Nephrology Dialysis Transplantation*, **34**: iii2–iii11.
- Jun, H.-R., Kim, H., Lee, S.-H., Cho, J.H., Lee, H., Yim, H.W., dkk., 2021, Onset of Hyperkalemia following the Administration of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker, *Cardiovascular Therapeutics*, **2021**: e5935149.
- Jun, M., Jardine, M.J., Perkovic, V., Pilard, Q., Billot, L., Rodgers, A., dkk., 2019, Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: A general practice-based, observational study, *PLOS ONE*, **14**: e0213192.
- Kovesdy, C.P., Matsushita, K., Sang, Y., Brunskill, N.J., Carrero, J.J., Chodick, G., dkk., 2018, Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis, *European Heart Journal*, **39**: 1535–1542.
- Lehnhardt, A. dan Kemper, M.J., 2011, Pathogenesis, diagnosis and management of hyperkalemia, *Pediatric Nephrology (Berlin, Germany)*, **26**: 377–384.
- Lepage, L., Dufour, A.-C., Doiron, J., Handfield, K., Desforges, K., Bell, R., dkk., 2015, Randomized Clinical Trial of Sodium Polystyrene Sulfonate for the Treatment of Mild Hyperkalemia in CKD, *Clinical journal of the American Society of Nephrology: CJASN*, **10**: 2136–2142.
- Levin, A., Stevens, P., Bilous, R.W., Coresh, J., Francisco, A., Jong, P.E., dkk., 2013, KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease, *Kidney International Supplements*, **3**: 1–150.
- Li, E.C., Heran, B.S., dan Wright, J.M., 2014, Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension, *The Cochrane Database of Systematic Reviews*, **2014**: CD009096.
- Manley-Casco, D. dan Berkowitz, P., 2020, A Whole Food Plant-Based Diet With a Novel Potassium-Binding Resin in a Patient With Advanced Chronic Kidney Disease, *American Journal of Lifestyle Medicine*, **14**: 592–594.
- Momoniati, T., Ilyas, D., dan Bhandari, S., 2019, ACE inhibitors and ARBs: Managing potassium and renal function, *Cleveland Clinic Journal of Medicine*, **86**: 601–607.
- Oktaviono, Y.H. dan Kusumawardhani, N., 2020, Hyperkalemia Associated with Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blockers in Chronic Kidney Disease, *Acta Medica Indonesiana*, **52**: 74.
- Palmer, B.F., Carrero, J.J., Clegg, D.J., Colbert, G.B., Emmett, M., Fishbane, S., dkk., 2021, Clinical Management of Hyperkalemia, *Mayo Clinic Proceedings*, **96**: 744–762.
- Palmer, B.F. dan Clegg, D.J., 2018, Hyperkalemia across the Continuum of Kidney Function, *Clinical Journal of the American Society of Nephrology : CJASN*, **13**: 155–157.

- Pitt, B., Bakris, G.L., Weir, M.R., Freeman, M.W., Lainscak, M., Mayo, M.R., dkk., 2018, Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN, *ESC heart failure*, **5**: 592–602.
- Qiao, Y., Shin, J., Chen, T., Inker, L., Coresh, J., Alexander, G., dkk., 2020, Association Between Renin-Angiotensin System Blockade Discontinuation and All-Cause Mortality Among Persons With Low Estimated Glomerular Filtration Rate, *JAMA internal medicine*, **180**: .
- Raebel, M.A., 2012, Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, *Cardiovascular Therapeutics*, **30**: e156-166.
- Saito, Y., Yamamoto, H., Nakajima, H., Takahashi, O., dan Komatsu, Y., 2017, Incidence of and risk factors for newly diagnosed hyperkalemia after hospital discharge in non-dialysis-dependent CKD patients treated with RAS inhibitors, *PLoS One*, **12**: .
- Saseen, J.J. dan MacLaughlin, E.J., 2017, Hypertension, dalam: *Pharmacotherapy: A Pathophysiologic Approach*, McGraw Hill, New York.
- Schmidt, M., Mansfield, K.E., Bhaskaran, K., Nitsch, D., Sørensen, H.T., Smeeth, L., dkk., 2017, Adherence to guidelines for creatinine and potassium monitoring and discontinuation following renin-angiotensin system blockade: a UK general practice-based cohort study, *BMJ open*, **7**: e012818.
- Thomsen, R.W., Nicolaisen, S.K., Hasvold, P., Sanchez, R.G., Pedersen, L., Adelborg, K., dkk., 2018, Elevated potassium levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes—a Danish population-based cohort study, *Nephrology Dialysis Transplantation*, **33**: 1610–1620.
- Tylicki, L., A, A., Lizakowski, S., Świetlik, D., dan Rutkowski, B., 2015, Management of renin-angiotensin system blockade in patients with chronic kidney disease under specialist care. Retrospective cross-sectional study, *Journal of the renin-angiotensin-aldosterone system : JRAAS*, **16**: .
- Walther, C.P., Winkelmayer, W.C., Richardson, P.A., Virani, S.S., dan Navaneethan, S.D., 2021, Renin-angiotensin system blocker discontinuation and adverse outcomes in chronic kidney disease, *Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association*, **36**: 1893–1899.
- Weir, M., Bushinsky, D., Benton, W., Woods, S., Mayo, M., Arthur, S., dkk., 2018, Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors, *American journal of medicine*, **131**: 555-564.e3.
- Weir, M.R., Bakris, G.L., Bushinsky, D.A., Mayo, M.R., Garza, D., Stasiv, Y., dkk., 2015, Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors, *The New England Journal of Medicine*, **372**: 211–221.

Whelton, P.K., Carey, R.M., Aronow, W.S., Casey, D.E., Collins, K.J., Dennison Himmelfarb, C., dkk., 2018, 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, *Hypertension (Dallas, Tex.: 1979)*, **71**: 1269–1324.